Drugs / TIL
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03658785 | Apr 2020 → Dec 2024 overdue | metachronous kidney Wilms' tumor, metastatic malignant neoplasm | Tongji Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TIL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03658785 ↗ |
| Modality | Cell therapy | “Adoptive cell transfer therapy that utilizes an autologous TIL manufacturing progress” NCT03658785 ↗ |
| Route | Intravenous | “cells will be infused intravenously over 20 to 30 minutes” NCT03658785 ↗ |